AU2014359276B2 - CMV vaccines - Google Patents

CMV vaccines Download PDF

Info

Publication number
AU2014359276B2
AU2014359276B2 AU2014359276A AU2014359276A AU2014359276B2 AU 2014359276 B2 AU2014359276 B2 AU 2014359276B2 AU 2014359276 A AU2014359276 A AU 2014359276A AU 2014359276 A AU2014359276 A AU 2014359276A AU 2014359276 B2 AU2014359276 B2 AU 2014359276B2
Authority
AU
Australia
Prior art keywords
cmv
glycoprotein
seq
arenavirus
replication
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014359276A
Other languages
English (en)
Other versions
AU2014359276A1 (en
Inventor
Mario Aistleithner
Andreas Aspock
Vera BAUMGARTL-STRASSER
Katharina BAYER
Bernhard BRIM
Katherine Cohen
Gerhard Fuhrmann
Farshad Guirakhoo
Manuela KAINER
Bettina KIEFMANN
Karen Lingnau
Thomas Monath
Elsa Muhlbacher
Klaus Orlinger
Elizabeth WATSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hookipa Biotech GmbH
Original Assignee
Hookipa Biotech GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hookipa Biotech GmbH filed Critical Hookipa Biotech GmbH
Publication of AU2014359276A1 publication Critical patent/AU2014359276A1/en
Assigned to HOOKIPA BIOTECH GMBH reassignment HOOKIPA BIOTECH GMBH Alteration of Name(s) of Applicant(s) under S113 Assignors: HOOKIPA BIOTECH AG
Application granted granted Critical
Publication of AU2014359276B2 publication Critical patent/AU2014359276B2/en
Priority to AU2021202541A priority Critical patent/AU2021202541A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C12N2760/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014359276A 2013-12-03 2014-12-03 CMV vaccines Active AU2014359276B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021202541A AU2021202541A1 (en) 2013-12-03 2021-04-26 CMV vaccines

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361911135P 2013-12-03 2013-12-03
US61/911,135 2013-12-03
US201462055699P 2014-09-26 2014-09-26
US62/055,699 2014-09-26
PCT/EP2014/076466 WO2015082570A1 (en) 2013-12-03 2014-12-03 Cmv vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202541A Division AU2021202541A1 (en) 2013-12-03 2021-04-26 CMV vaccines

Publications (2)

Publication Number Publication Date
AU2014359276A1 AU2014359276A1 (en) 2016-06-16
AU2014359276B2 true AU2014359276B2 (en) 2021-01-28

Family

ID=52232138

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014359276A Active AU2014359276B2 (en) 2013-12-03 2014-12-03 CMV vaccines
AU2021202541A Abandoned AU2021202541A1 (en) 2013-12-03 2021-04-26 CMV vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021202541A Abandoned AU2021202541A1 (en) 2013-12-03 2021-04-26 CMV vaccines

Country Status (17)

Country Link
US (3) US10111945B2 (enExample)
EP (2) EP3077519B1 (enExample)
JP (2) JP6818551B2 (enExample)
CN (2) CN105980570B (enExample)
AU (2) AU2014359276B2 (enExample)
CA (1) CA2932318C (enExample)
CY (1) CY1124288T1 (enExample)
DK (1) DK3077519T3 (enExample)
ES (1) ES2868427T3 (enExample)
HR (1) HRP20211015T1 (enExample)
HU (1) HUE054579T2 (enExample)
LT (1) LT3077519T (enExample)
PL (1) PL3077519T3 (enExample)
PT (1) PT3077519T (enExample)
RS (1) RS61993B1 (enExample)
SI (1) SI3077519T1 (enExample)
WO (1) WO2015082570A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2604695B1 (en) 2007-12-27 2022-11-16 Universität Zürich Replication-defective arenavirus vectors
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
PL3218504T3 (pl) 2014-11-13 2021-02-08 Université De Genève Trójsegmentowe arenawirusy jako wektory szczepionkowe
EP3031822A1 (en) * 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
WO2016198531A2 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
CA3002922A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
CN108779472B (zh) 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
US11266727B2 (en) 2015-11-12 2022-03-08 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
US11260090B2 (en) 2016-03-08 2022-03-01 University Of Vermont And State Agricultural College Modified arenavirus
IL262207B1 (en) 2016-04-15 2025-09-01 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
EP3528821A4 (en) * 2016-10-21 2020-07-01 ModernaTX, Inc. HUMAN CYTOMEGALOVIRUS VACCINE
US20200206334A1 (en) 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
IL269892B2 (en) 2017-04-14 2024-04-01 Regenxbio Inc Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2 sulfatase (ids) produced by human neural or glial cells
WO2018204080A1 (en) * 2017-05-02 2018-11-08 The Scripps Research Institute Compositions and methods related to arenavirus immunogens
WO2019216929A1 (en) * 2018-05-11 2019-11-14 City Of Hope Mva vectors for expressing multiple cytomegalovirus (cmv) antigens and use thereof
MX2021004273A (es) 2018-10-17 2021-12-10 Glaxosmithkline Biologicals Sa Proteinas de citomegalovirus modificadas y complejos estabilizados.
CN113164585B (zh) * 2018-12-10 2023-08-29 Km生物医薬股份公司 用于预防或治疗巨细胞病毒的先天性感染的疫苗
CN114981443A (zh) * 2019-11-07 2022-08-30 巴塞尔大学 作为载体的沙粒病毒
US20230248821A1 (en) * 2020-06-09 2023-08-10 Km Biologics Co., Ltd. Fusion Protein of Pentamer and GB of Cytomegalovirus, and Vaccine Containing Said Fusion Protein
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
RU2756557C1 (ru) * 2020-11-02 2021-10-01 Федеральное государственное бюджетное учреждение "Федеральный центр охраны здоровья животных" (ФГБУ "ВНИИЗЖ") Способ опосредованного определения титра вируса ящура в неинактивированном сырье для вакцины при амплификации вирусной нуклеиновой кислоты и детекции РНК-ампликонов с применением технологии молекулярных биконов
KR20230145386A (ko) 2021-02-10 2023-10-17 리젠엑스바이오 인크. 재조합 인간 이두로네이트-2-설파타아제(ids)를 사용한 점액다당류증 ii의 치료
US20240229073A1 (en) 2021-05-13 2024-07-11 Hookipa Biotech Gmbh Arenaviruses as vectors
WO2024163912A2 (en) * 2023-02-03 2024-08-08 The Children's Medical Center Corporation Vaccine and therapeutic protein delivery compositions comprising fusion proteins
WO2025056782A1 (en) 2023-09-15 2025-03-20 Hookipa Biotech Gmbh Arenavirus formulations, methods and uses thereof
CN118221773B (zh) * 2024-02-05 2025-09-09 首都医科大学附属北京儿童医院保定医院 与HLA相关的CMV pp65表位疫苗组合物与应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008074A1 (de) * 2004-07-16 2006-01-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider tumore durch retrovirale, mit arenavirus-glykoprotein pseudotypisierte vektoren
WO2009083210A1 (en) * 2007-12-27 2009-07-09 Universität Zürich Replication-defective arenavirus vectors
US20100316667A1 (en) * 2009-06-05 2010-12-16 Don Diamond Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof
WO2012049317A2 (en) * 2010-10-15 2012-04-19 Glaxosmithkline Biologicals S.A. Novel antigen
WO2012093340A2 (en) * 2011-01-07 2012-07-12 Bioscience Slovakia Viral diagnostics
WO2013054199A2 (en) * 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
JP2607712B2 (ja) * 1988-01-29 1997-05-07 カイロン コーポレイション 組換えｃｍｖ中和タンパク
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP1265916B1 (en) * 2000-03-21 2005-12-21 Genzyme Corporation Therapeutic anti-cytomegalovirus compounds
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
CA2646891A1 (en) 2006-03-23 2007-09-27 Novartis Ag Immunopotentiating compounds
ES2376492T3 (es) 2006-03-23 2012-03-14 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores.
JP2012530500A (ja) * 2009-06-26 2012-12-06 ヴェクトライト バイオメディカ インコーポレイテッド サイトメガロウイルス由来のペプチドを含む免疫原組成物および使用方法
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
EP3854413A1 (en) * 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US8834307B2 (en) 2011-10-06 2014-09-16 Kawasaki Jukogyo Kabushiki Kaisha Belt type continuously variable transmission
MX378747B (es) * 2012-07-06 2025-03-10 Glaxosmithkline Biologicals S A Star Complejos de proteínas de citomegalovirus.
US9809801B2 (en) 2013-03-15 2017-11-07 Université De Genève Anti-mycobacterial vaccines
AU2014359276B2 (en) 2013-12-03 2021-01-28 Hookipa Biotech Gmbh CMV vaccines
PL3218504T3 (pl) 2014-11-13 2021-02-08 Université De Genève Trójsegmentowe arenawirusy jako wektory szczepionkowe
WO2016198531A2 (en) 2015-06-10 2016-12-15 Hookipa Biotech Ag Hpv vaccines
CN108779472B (zh) 2015-11-04 2022-09-09 霍欧奇帕生物科技有限公司 针对乙型肝炎病毒的疫苗
US11266727B2 (en) 2015-11-12 2022-03-08 Hookipa Biotech Gmbh Arenavirus particles as cancer vaccines
MX2018013956A (es) 2016-05-18 2019-07-04 Hookipa Biotech Gmbh Virus pichinde de tres segmentos como vectores de vacunas.
US20200206334A1 (en) 2016-11-04 2020-07-02 Hookipa Biotech Gmbh Replication-deficient arenavirus particles and tri-segmented arenavirus particles as cancer vaccines
US20200113995A1 (en) 2017-04-07 2020-04-16 Hookipa Biotech Gmbh Arenavirus particles to treat solid tumors
CN114981443A (zh) 2019-11-07 2022-08-30 巴塞尔大学 作为载体的沙粒病毒
IL298420A (en) 2020-05-29 2023-01-01 Hookipa Biotech Gmbh Cancer treatment strategies using RNA virus vectors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006008074A1 (de) * 2004-07-16 2006-01-26 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Gentherapie solider tumore durch retrovirale, mit arenavirus-glykoprotein pseudotypisierte vektoren
WO2009083210A1 (en) * 2007-12-27 2009-07-09 Universität Zürich Replication-defective arenavirus vectors
US20100316667A1 (en) * 2009-06-05 2010-12-16 Don Diamond Genetically stable recombinant modified vaccinia ankara (rmva) vaccines and methods of preparation thereof
WO2012049317A2 (en) * 2010-10-15 2012-04-19 Glaxosmithkline Biologicals S.A. Novel antigen
WO2012093340A2 (en) * 2011-01-07 2012-07-12 Bioscience Slovakia Viral diagnostics
WO2013054199A2 (en) * 2011-10-12 2013-04-18 Novartis Ag Cmv antigens and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FLATZ, Lukas et al., Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. NATURE MEDICINE, vol. 16, no. 3, 7 February 2010, pages 339-345 *
FOUTS, Ashley E et al., JOURNAL OF VIROLOGY, vol. 86, no. 13, 24 April 2012, pages 7444-7447 *
ZHONG, Jie et al., Induction of Pluripotent Protective Immunity Following Immunisation with a Chimeric Vaccine against Human Cytomegalovirus. PLOS ONE, vol. 3, no. 9, 22 September 2008, page e3256 *

Also Published As

Publication number Publication date
PT3077519T (pt) 2021-05-13
JP6818551B2 (ja) 2021-01-20
EP3904522A1 (en) 2021-11-03
SI3077519T1 (sl) 2021-07-30
JP7001807B2 (ja) 2022-02-04
WO2015082570A1 (en) 2015-06-11
AU2021202541A1 (en) 2021-05-27
HUE054579T2 (hu) 2021-09-28
CA2932318C (en) 2023-10-10
CN105980570B (zh) 2022-06-07
JP2021061848A (ja) 2021-04-22
CN115058452A (zh) 2022-09-16
DK3077519T3 (en) 2021-06-14
US11554169B2 (en) 2023-01-17
US20190247493A1 (en) 2019-08-15
CY1124288T1 (el) 2022-07-22
US10111945B2 (en) 2018-10-30
RS61993B1 (sr) 2021-07-30
JP2017503482A (ja) 2017-02-02
HK1226440A1 (zh) 2017-09-29
CA2932318A1 (en) 2015-06-11
CN105980570A (zh) 2016-09-28
EP3077519B1 (en) 2021-03-31
US20230181725A1 (en) 2023-06-15
LT3077519T (lt) 2021-04-26
AU2014359276A1 (en) 2016-06-16
PL3077519T3 (pl) 2021-10-18
US20160296619A1 (en) 2016-10-13
ES2868427T3 (es) 2021-10-21
HRP20211015T1 (hr) 2021-10-01
WO2015082570A8 (en) 2015-11-26
EP3077519A1 (en) 2016-10-12

Similar Documents

Publication Publication Date Title
AU2014359276B2 (en) CMV vaccines
AU2021232660B2 (en) HPV vaccines
AU2016348675B2 (en) Vaccines against Hepatitis B virus
Paillot et al. Equine herpes virus-1: virus, immunity and vaccines
CN110719788A (zh) 治疗实体瘤的沙粒病毒颗粒
JP2023520080A (ja) Ｃｏｖｉｄ－１９に対する保護のための弱毒化されたポックスウイルスベクターをベースとするワクチン
JP2019533437A (ja) 新規なｅｈｖ挿入部位ｏｒｆ７０
HK40063367A (en) Cmv vaccines
HK40082300A (en) Hpv vaccines
HK1226440B (en) Cmv vaccines
HK1263252A1 (en) Vaccines against hepatitis b virus
HK1263252B (en) Vaccines against hepatitis b virus

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: HOOKIPA BIOTECH GMBH

Free format text: FORMER NAME(S): HOOKIPA BIOTECH AG

FGA Letters patent sealed or granted (standard patent)